Coverage
-
September 21, 2022
Three drug manufacturers for Viatris have urged a Pennsylvania federal judge to cut them loose from a patent suit lodged by a Johnson & Johnson branch over a generic multiple sclerosis treatment, arguing that the court lacks jurisdiction and the overseas suppliers can't be held liable for the allegedly infringing products.
1 other articles on this case.
View all »